KURA ONCOLOGY INC. - COMMON STOCK

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

07 Mar 2024 09:45:19 By NetDania Notify

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

06 Mar 2024 11:15:16 By NetDania Notify

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

06 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 17:00:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

27 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

26 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

22 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

20 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

30 Jan 2024 10:08:20 By NetDania Notify

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

30 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

24 Jan 2024 09:45:23 By NetDania Notify

Kura Oncology Announces Oversubscribed $150 Million Private Placement

24 Jan 2024 07:00:57 By Nasdaq GlobeNewswire

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

08 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

28 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2023 Financial Results

02 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

02 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2023 Financial Results

26 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire